During the past decade, Fundação São Francisco Xavier conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Fundação São Francisco Xavier" are "Advanced or Metastatic Non-small Cell Lung Cancer" (1 trials), "Carcinoma, Non-Small-Cell Lung" (1 trials), "Castration-Resistant Prostatic Cancer" (1 trials), "Metastatic Castrate Sensitive Prostate Cancer" (1 trials) and "Metastatic Prostate Cancer" (1 trials). Many other conditions were trialed in "Fundação São Francisco Xavier" in a lesser frequency.

Most popular intervention types in "Fundação São Francisco Xavier" are "Drug" (4 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Lazertinib" (2 trials), "Niraparib" (2 trials), "Prednisone" (2 trials), "Abiraterone Acetate" (1 trials) and "Abiraterone acetate (AA)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Fundação São Francisco Xavier" are 3 trials for "Male" genders and 2 trials for "All" genders.

Currently, there are NaN active trials in "Fundação São Francisco Xavier". undefined are not yet recruiting, 3 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Fundação São Francisco Xavier, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Fundação São Francisco Xavier, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".